According to the aforementioned studies, PSC has higher PD‐L1 positivity rates compared to conventional NSCLC, suggesting that PD‐L1 inhibitors may be an optimal treatment for PSC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.